The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses important factors to consider when selecting BTK inhibitors for patients with Waldenström’s macroglobulinemia (WM), referencing findings from the ASPEN trial (NCT03053440). Dr Treon further comments on the need to consider a patient’s genomics and the side effect profile of these agents before deciding on a treatment course. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
